在跨性别成年人中,丸激素治疗对细胞染色体P450 3A和P-糖蛋白活性使用米达佐拉姆和迪戈辛作为探针基质的影响
Michiko Hunter1, Rene Coig1, Linda Risler1
1Department of Pharmacy, University of Washington, Seattle, Washington, USA.
Pharmacotherapy
|December 26, 2025
概括
确认性别的丸激素治疗并没有显著改变由CYP3A酶或P-糖蛋白运输的药物代谢. 这表明通过这些途径处理的药物的药理动力学的影响最小,尽管建议对治疗指数狭窄的药物保持谨慎.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 跨性别者健康 跨性别者健康
背景情况:
- 性别确认丸激素治疗是跨性别成年人的标准医疗干预.
- 有限的数据存在于丸激素对药物代谢酶和转运体的影响.
- 了解这些相互作用对于安全有效的联合使用药物至关重要.
研究的目的:
- 研究性别肯定性丸激素治疗对细胞染色体P450 (CYP) 3A和P-糖蛋白活动的影响.
- 评估对米达佐拉姆 (CYP3A基质) 和狄戈辛 (P-糖蛋白基质) 药理动学的影响.
主要方法:
- 一项纵向的前性研究,涉及跨性别成年人开始丸激素治疗.
- 参与者在基线时接受口服米达佐拉姆和迪戈辛,在开始丸激素后1个月和3个月.
- 用液体染色学-并联质谱法和非分区方法分析了药理动力学参数.
主要成果:
- 14名参与者完成了这项研究,观察到总丸激素水平显著增加.
- 在基线和丸激素治疗阶段之间,在米达佐拉姆,其代谢物或狄戈辛的药理动力学参数中没有发现显著差异.
- 在丸激素治疗期间,明显的CYP3A和P-糖蛋白活性保持不变.
结论:
- 确认性别的丸激素疗法不会显著改变CYP3A或P-糖蛋白活性.
- 通过CYP3A代谢或通过P-糖蛋白运输的药物的药理学不太可能受到显著的影响.
- 建议在与丸激素治疗同时使用时,对治疗指数狭窄的药物进行临床谨慎.
更多相关视频
相关概念视频
Factors Affecting Drug Biotransformation: Biological
491
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
491
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Pharmacokinetics: Drug–Drug Interactions
316
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
316
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
178
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
178
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
165
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165


